AG˹ٷ

STOCK TITAN

[Form 4] Clover Health Investments, Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Form 4 highlights: On 31 Jul 2025, Clover Health (CLOV) officer Conrad Wai had 27,930 Class A shares withheld at $2.89 (Code F) to satisfy tax on the vesting of 12.5 % of an RSU grant dated 31 Oct 2023. The withheld amount equals roughly 1.7 % of his direct stake.

Post-transaction holdings: Wai still controls 1,671,837 shares directly and 1,403,701 shares indirectly through a family trust—about 3.08 M shares in total—so economic exposure remains virtually unchanged.

Investor takeaway: Because the disposition is automatic, not an open-market trade, it conveys no bearish signal. Remaining RSUs continue to vest quarterly until 31 Oct 2025, maintaining long-term alignment between the executive and shareholders. Market impact is expected to be minimal.

Punti salienti del Modulo 4: Il 31 luglio 2025, l'ufficiale di Clover Health (CLOV), Conrad Wai, ha trattenuto 27.930 azioni di Classe A a $2,89 (Codice F) per coprire le tasse relative al vesting del 12,5% di un grant di RSU datato 31 ottobre 2023. La quantità trattenuta corrisponde a circa l'1,7% della sua partecipazione diretta.

Detenzione dopo la transazione: Wai detiene ancora direttamente 1.671.837 azioni e indirettamente 1.403.701 azioni tramite un trust familiare, per un totale di circa 3,08 milioni di azioni, quindi l'esposizione economica resta praticamente invariata.

Considerazioni per gli investitori: Poiché la disposizione è automatica e non una vendita sul mercato aperto, non rappresenta un segnale ribassista. Le RSU rimanenti continueranno a maturare trimestralmente fino al 31 ottobre 2025, mantenendo un allineamento a lungo termine tra il dirigente e gli azionisti. L'impatto sul mercato è previsto minimo.

Aspectos destacados del Formulario 4: El 31 de julio de 2025, el directivo de Clover Health (CLOV), Conrad Wai, retuvo 27,930 acciones Clase A a $2.89 (Código F) para cubrir impuestos sobre la adquisición del 12.5% de una concesión de RSU fechada el 31 de octubre de 2023. La cantidad retenida equivale aproximadamente al 1.7% de su participación directa.

Participaciones después de la transacción: Wai aún controla directamente 1,671,837 acciones e indirectamente 1,403,701 acciones a través de un fideicomiso familiar, sumando alrededor de 3.08 millones de acciones en total, por lo que la exposición económica permanece prácticamente sin cambios.

Conclusión para inversores: Dado que la disposición es automática y no una operación en el mercado abierto, no transmite una señal bajista. Las RSU restantes seguirán consolidándose trimestralmente hasta el 31 de octubre de 2025, manteniendo la alineación a largo plazo entre el ejecutivo y los accionistas. Se espera un impacto mínimo en el mercado.

Form 4 주요 내용: 2025� 7� 31�, Clover Health(CLOV) 임원 콘래� 와이는 2023� 10� 31일에 부여된 RSU� 12.5% 베스팅에 따른 세금 납부� 위해 $2.89(코드 F)� 27,930주의 클래� A 주식� 원천징수했습니다. 원천징수� 수량은 그의 직접 지분의 � 1.7%� 해당합니�.

거래 � 보유 주식: 와이는 여전� 직접 1,671,837�, 가� 신탁� 통해 간접적으� 1,403,701주를 보유하고 있어 � � 308� 주를 보유 중이�, 경제� 노출은 사실� 변함이 없습니다.

투자� 시사�: � 처분은 자동으로 이루어지� 것이� 공개 시장에서� 거래가 아니므� 약세 신호� 나타내지 않습니다. 남은 RSU� 2025� 10� 31일까지 분기별로 계속 베스팅되� 임원� 주주 간의 장기적인 이해관� 일치� 유지합니�. 시장� 미치� 영향은 최소� 예상됩니�.

Points forts du formulaire 4 : Le 31 juillet 2025, l'officier de Clover Health (CLOV), Conrad Wai, a retenu 27 930 actions de Classe A au prix de 2,89 $ (Code F) pour couvrir l'impôt lié à la levée de 12,5 % d'une attribution de RSU datée du 31 octobre 2023. Le montant retenu représente environ 1,7 % de sa participation directe.

Détentions après la transaction : Wai contrôle toujours directement 1 671 837 actions et indirectement 1 403 701 actions via une fiducie familiale � soit environ 3,08 millions d'actions au total � ce qui signifie que l'exposition économique reste pratiquement inchangée.

À retenir pour les investisseurs : Étant donné que la cession est automatique et non une transaction sur le marché ouvert, elle ne constitue pas un signal baissier. Les RSU restantes continueront à être acquises trimestriellement jusqu'au 31 octobre 2025, maintenant ainsi un alignement à long terme entre le dirigeant et les actionnaires. L'impact sur le marché devrait être minimal.

Formular 4 Highlights: Am 31. Juli 2025 hat Clover Health (CLOV) Geschäftsführer Conrad Wai 27.930 Class A Aktien zum Preis von 2,89 $ (Code F) einbehalten, um die Steuer auf die Vesting von 12,5 % einer RSU-Zuteilung vom 31. Oktober 2023 zu begleichen. Die einbehaltene Menge entspricht etwa 1,7 % seines direkten Anteils.

Bestände nach der Transaktion: Wai kontrolliert weiterhin direkt 1.671.837 Aktien und indirekt 1.403.701 Aktien über einen Familientrust � insgesamt also rund 3,08 Millionen Aktien � sodass die wirtschaftliche Beteiligung praktisch unverändert bleibt.

Investorenausblick: Da die Veräußerung automatisch erfolgt und kein Handel am offenen Markt ist, signalisiert dies keinen Bärenmarkt. Die verbleibenden RSUs werden weiterhin vierteljährlich bis zum 31. Oktober 2025 vesten, was eine langfristige Ausrichtung zwischen dem Geschäftsführer und den Aktionären sicherstellt. Die Marktauswirkung wird voraussichtlich minimal sein.

Positive
  • Executive retains roughly 3.08 M shares, underscoring sustained equity alignment with shareholders.
Negative
  • 27,930 shares were disposed of (withheld) to cover taxes, modestly increasing share count dilution, though immaterial to investors.

Insights

TL;DR: Tax-withholding disposition; no sentiment change, negligible impact.

The Code F transaction merely covers withholding taxes on RSU vesting. Wai’s aggregate ownership stays above 3 M shares, so insider exposure is intact. The withheld 27,930 shares represent <1 % of CLOV’s average daily volume and 0.08 % of shares outstanding—too small to move the stock. No bullish or bearish inference should be drawn.

TL;DR: Routine compliance event; alignment with shareholders preserved.

The filing demonstrates proper Section 16 reporting and a standard tax-settlement mechanism. Continued vesting through Oct 2025 incentivizes performance. No red flags on governance or insider confidence arise from this disclosure.

Punti salienti del Modulo 4: Il 31 luglio 2025, l'ufficiale di Clover Health (CLOV), Conrad Wai, ha trattenuto 27.930 azioni di Classe A a $2,89 (Codice F) per coprire le tasse relative al vesting del 12,5% di un grant di RSU datato 31 ottobre 2023. La quantità trattenuta corrisponde a circa l'1,7% della sua partecipazione diretta.

Detenzione dopo la transazione: Wai detiene ancora direttamente 1.671.837 azioni e indirettamente 1.403.701 azioni tramite un trust familiare, per un totale di circa 3,08 milioni di azioni, quindi l'esposizione economica resta praticamente invariata.

Considerazioni per gli investitori: Poiché la disposizione è automatica e non una vendita sul mercato aperto, non rappresenta un segnale ribassista. Le RSU rimanenti continueranno a maturare trimestralmente fino al 31 ottobre 2025, mantenendo un allineamento a lungo termine tra il dirigente e gli azionisti. L'impatto sul mercato è previsto minimo.

Aspectos destacados del Formulario 4: El 31 de julio de 2025, el directivo de Clover Health (CLOV), Conrad Wai, retuvo 27,930 acciones Clase A a $2.89 (Código F) para cubrir impuestos sobre la adquisición del 12.5% de una concesión de RSU fechada el 31 de octubre de 2023. La cantidad retenida equivale aproximadamente al 1.7% de su participación directa.

Participaciones después de la transacción: Wai aún controla directamente 1,671,837 acciones e indirectamente 1,403,701 acciones a través de un fideicomiso familiar, sumando alrededor de 3.08 millones de acciones en total, por lo que la exposición económica permanece prácticamente sin cambios.

Conclusión para inversores: Dado que la disposición es automática y no una operación en el mercado abierto, no transmite una señal bajista. Las RSU restantes seguirán consolidándose trimestralmente hasta el 31 de octubre de 2025, manteniendo la alineación a largo plazo entre el ejecutivo y los accionistas. Se espera un impacto mínimo en el mercado.

Form 4 주요 내용: 2025� 7� 31�, Clover Health(CLOV) 임원 콘래� 와이는 2023� 10� 31일에 부여된 RSU� 12.5% 베스팅에 따른 세금 납부� 위해 $2.89(코드 F)� 27,930주의 클래� A 주식� 원천징수했습니다. 원천징수� 수량은 그의 직접 지분의 � 1.7%� 해당합니�.

거래 � 보유 주식: 와이는 여전� 직접 1,671,837�, 가� 신탁� 통해 간접적으� 1,403,701주를 보유하고 있어 � � 308� 주를 보유 중이�, 경제� 노출은 사실� 변함이 없습니다.

투자� 시사�: � 처분은 자동으로 이루어지� 것이� 공개 시장에서� 거래가 아니므� 약세 신호� 나타내지 않습니다. 남은 RSU� 2025� 10� 31일까지 분기별로 계속 베스팅되� 임원� 주주 간의 장기적인 이해관� 일치� 유지합니�. 시장� 미치� 영향은 최소� 예상됩니�.

Points forts du formulaire 4 : Le 31 juillet 2025, l'officier de Clover Health (CLOV), Conrad Wai, a retenu 27 930 actions de Classe A au prix de 2,89 $ (Code F) pour couvrir l'impôt lié à la levée de 12,5 % d'une attribution de RSU datée du 31 octobre 2023. Le montant retenu représente environ 1,7 % de sa participation directe.

Détentions après la transaction : Wai contrôle toujours directement 1 671 837 actions et indirectement 1 403 701 actions via une fiducie familiale � soit environ 3,08 millions d'actions au total � ce qui signifie que l'exposition économique reste pratiquement inchangée.

À retenir pour les investisseurs : Étant donné que la cession est automatique et non une transaction sur le marché ouvert, elle ne constitue pas un signal baissier. Les RSU restantes continueront à être acquises trimestriellement jusqu'au 31 octobre 2025, maintenant ainsi un alignement à long terme entre le dirigeant et les actionnaires. L'impact sur le marché devrait être minimal.

Formular 4 Highlights: Am 31. Juli 2025 hat Clover Health (CLOV) Geschäftsführer Conrad Wai 27.930 Class A Aktien zum Preis von 2,89 $ (Code F) einbehalten, um die Steuer auf die Vesting von 12,5 % einer RSU-Zuteilung vom 31. Oktober 2023 zu begleichen. Die einbehaltene Menge entspricht etwa 1,7 % seines direkten Anteils.

Bestände nach der Transaktion: Wai kontrolliert weiterhin direkt 1.671.837 Aktien und indirekt 1.403.701 Aktien über einen Familientrust � insgesamt also rund 3,08 Millionen Aktien � sodass die wirtschaftliche Beteiligung praktisch unverändert bleibt.

Investorenausblick: Da die Veräußerung automatisch erfolgt und kein Handel am offenen Markt ist, signalisiert dies keinen Bärenmarkt. Die verbleibenden RSUs werden weiterhin vierteljährlich bis zum 31. Oktober 2025 vesten, was eine langfristige Ausrichtung zwischen dem Geschäftsführer und den Aktionären sicherstellt. Die Marktauswirkung wird voraussichtlich minimal sein.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wai Conrad

(Last) (First) (Middle)
C/O CLOVER HEALTH INVESTMENTS, CORP.
NOT APPLICABLE

(Street)
WILMINGTON DE 19801

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEO, Counterpart Health
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 07/31/2025 F 27,930(1) D $2.89 1,671,837 D
Class A Common Stock 1,403,701 I By Trust.(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations upon the vesting, on July 31, 2025, of 12.5% of the original number of time-based restricted stock units ("RSUs") granted to the Reporting Person on October 31, 2023, and timely reported on a Form 4 filed on November 2, 2023. The remaining RSUs have a final vesting date occurring on October 31, 2025, subject to the continued service of the Reporting Person on each such vesting date.
2. Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee.
Remarks:
/s/ Peter J. Rivas as attorney-in-fact for Conrad Wai 08/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Clover Health shares did Conrad Wai dispose of?

27,930 Class A shares were automatically withheld to pay tax on RSU vesting.

What was the transaction price for CLOV shares?

The shares were valued at $2.89 per share for tax-withholding purposes.

How many CLOV shares does Conrad Wai own after the transaction?

He owns 1,671,837 shares directly and 1,403,701 shares indirectly via a family trust.

Does this Form 4 indicate insider selling pressure on CLOV?

No. The Code F transaction is an automatic tax-withholding event, not an open-market sale.

When will the remaining RSUs vest for Conrad Wai?

The final vesting date for the RSUs is 31 Oct 2025, subject to continued service.
Clover Health Investments Corp

NASDAQ:CLOV

CLOV Rankings

CLOV Latest News

CLOV Latest SEC Filings

CLOV Stock Data

1.41B
400.32M
3.77%
27.27%
7.11%
Healthcare Plans
Hospital & Medical Service Plans
United States
JERSEY CITY